Health Care

4444 posts

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…
In vitro fertilisation

Monash IVF soars to 85cps as company rejects takeover offer despite -33% YTD returns

Monash IVF Group has soared +40% on Monday morning as the company rejected a non-binding takeover…
Prostate cancer examination discussion concept

Orthocell pops on nerve healing successes in prostate surgery patients

Orthocell has seen its share price jump on Thursday as the company unveils its latest early-stage…
Biotech chart concept

AFT Pharmaceuticals jumps +10% on $115M interim FY26 record revenue

AFT Pharmaceuticals has seen its price jump +10% just shy of $3/sh on Thursday morning as…
European Medicine Agency headquarters

Prescient Therapeutics jumps +15% on EU regulator interest in PTX-100

Prescient Therapeutics has jumped +15% after EU drug regulator European Medicines Agency awarded orphan drug designation.
CSL information on the logo of the office facade.

CSL to pour $2.3 billion into US investments in attempt to dodge Trump’s tariffs

CSL Ltd will be wielding as much as $2.3 billion as a weapon against Trump's U.S.…
Image of t-cells

Race Oncology launches fresh myeloid leukemia and lung cancer trials with RC220

Race Oncology has sought to expand the total addressable markets it can reach with its cancer…
Eye

PYC reports Phase II success in treating degenerative blindness condition

PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type
US defence health concept

Renerve pops +80% as US defence, veterans affairs depts approve nerve healing product

Renerve has seen its shares rocket as much as +80% higher on Thursday, to 19cps, as…
What's goin' on there lad

Something going on there: Zoono Group rockets +63% on no news, then pauses mid-morning

The flows of prices are sometimes a case of more questions than answers, and that's the…